In Depth Observational Clinical Trial Of Retinitis Pigmentosa Patients

NCT05849987 | Not Yet Recruiting

• 1 other identifier: 92030990
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Typically, clinical research participation favors a specific demographic group, and little research exists on how trial attributes affect participation. As such, this study seeks to analyze data from different demographic groups and check for recurring trends that could provide valuable insights for future retinitis pigmentosa patients.

Conditions

Retinitis Pigmentosa

Keywords

retinitis pigmentosa

Outcome Measures

Primary Outcomes (2)

• Number of patient decides to enroll in clinical trial

  3 months

• Rate of patients who remain in clinical trial to trial completion

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Retinitis Pigmentosa patients who are actively considering enrolling in an interventional clinical trial, but have not yet completed enrollment and registration.

You may qualify if:

• Is 18+ years old
• Confirmed diagnosis of retinitis pigmentosa
• Signed Written Informed Consent

You may not qualify if:

• Inability to perform regular electronic reporting
• Participant is actively receiving study therapy in another trial
• Women of childbearing potential without a negative pregnancy test; or women who are lactating.

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Related Publications (3)

• Miura G, Sugawara T, Kawasaki Y, Tatsumi T, Nizawa T, Baba T, Hanaoka H, Yamamoto S. Clinical Trial to Evaluate Safety and Efficacy of Transdermal Electrical Stimulation on Visual Functions of Patients with Retinitis Pigmentosa. Sci Rep. 2019 Aug 12;9(1):11668. doi: 10.1038/s41598-019-48158-5.

  PMID: 31406205 BACKGROUND

• Arslan U, Ozmert E, Demirel S, Ornek F, Sermet F. Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results. Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):893-908. doi: 10.1007/s00417-018-3953-5. Epub 2018 Mar 15.

  PMID: 29546474 BACKGROUND

• Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004 Sep;122(9):1297-305. doi: 10.1001/archopht.122.9.1297.

  PMID: 15364708 BACKGROUND

MeSH Terms

Conditions

Retinitis Pigmentosa

Condition Hierarchy (Ancestors)

Eye Diseases, Hereditary; Eye Diseases; Retinal Dystrophies; Retinal Degeneration; Retinal Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

4159004227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2023
• First Posted: May 9, 2023
• Study Start: May 1, 2024
• Primary Completion: May 1, 2025
• Study Completion: May 1, 2026
• Last Updated: May 9, 2023

Record last verified: 2023-04